The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APDN | -97.76% | -100% | -87.62% | -100% |
| S&P | +12.66% | +85.37% | +13.13% | +669% |
Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
No news articles found for Bnb Plus.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.30M | -61.8% |
| Gross Profit | -$0.07M | -165.9% |
| Gross Margin | -24.05% | -38.0% |
| Market Cap | $2.67M | 858.3% |
| Market Cap / Employee | $0.06M | 0.0% |
| Employees | 48 | 0.0% |
| Net Income | -$3.65M | -297.2% |
| EBITDA | -$3.62M | -12.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.73M | -54.7% |
| Accounts Receivable | $0.20M | -61.3% |
| Inventory | 0.3 | -27.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.33M | -37.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -96.52% | -51.6% |
| Return On Invested Capital | -130.24% | 230.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.64M | 24.9% |
| Operating Free Cash Flow | -$2.63M | 24.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.73 | 0.87 | 1.00 | 0.21 | -103.59% |
| Price to Sales | 1.95 | 1.72 | 0.78 | 0.89 | 85.17% |
| Price to Tangible Book Value | 517.76 | 244.85 | 2.68 | 0.28 | -100.37% |
| Enterprise Value to EBITDA | -0.26 | 0.85 | 1.09 | 0.48 | -81.09% |
| Return on Equity | -99.2% | -100.4% | -141.4% | -130.8% | 76.19% |
| Total Debt | $0.74M | $0.61M | $0.47M | $0.33M | -61.48% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
